Potassium News and Research

RSS

Centocor Ortho Biotech receives FDA approval for Zytiga to treat prostate cancer

The U.S. Food and Drug Administration today approved Zytiga in combination with prednisone to treat patients with late-stage castration-resistant prostate cancer who have received prior docetaxel.

28 Apr 2011

AstraZeneca announces U.S. availability of vandetanib for rare medullary thyroid cancer

AstraZeneca today announced that the orphan drug vandetanib is now available to U.S. patients for the treatment of medullary thyroid cancer that cannot be removed by surgery or that has spread to other parts of the body.

25 Apr 2011

Bayer's oral contraceptives may increase risk of blood clots, stroke or heart attack

Bayer HealthCare Pharmaceuticals, Inc. is aware of two studies published today in The British Medical Journal, ONLINE FIRST.

25 Apr 2011

Fleming ramps up production of ThyroShield to meet increased domestic and international demand

Fleming Pharmaceuticals, maker of ThyroShield– the only FDA approved liquid potassium iodide product indicated for thyroid protection in radiation emergencies – announced today that it has implemented the changes necessary to ramp up production to meet increased domestic and international demand.

22 Apr 2011

Salix Pharmaceuticals receives three U.S. patents relating to rifaximin

Salix Pharmaceuticals, Ltd. today announced that the U.S. Patent and Trademark Office has issued three patents relating to rifaximin.

21 Apr 2011

Acorda receives patent for AMPYRA tablets to improve walking in MS patients

Acorda Therapeutics, Inc. today announced that the United States Patent and Trademark Office has allowed U.S. Patent Application No. 11/010,828 entitled "Sustained Release Aminopyridine Composition."

20 Apr 2011

Children who consume white potatoes have more nutrient-dense diets

Research to be presented this week at The Federation of American Societies for Experimental Biology Conference in Washington, D.C., demonstrates that consumption of white potatoes by children does not displace other vegetables from children's meals.

12 Apr 2011

Shionogi launches CUVPOSA for pediatric chronic severe drooling

Shionogi Inc., the U.S.-based group company of Shionogi & Co., Ltd., today announced the U.S. commercial availability of CUVPOSA™ (glycopyrrolate) oral solution, the first and only FDA-approved treatment to reduce chronic severe drooling in patients aged 3 to 16 with neurologic conditions associated with problem drooling, such as cerebral palsy.

7 Apr 2011

AstraZeneca's vandetanib receives FDA approval in medullary thyroid cancer

AstraZeneca today announced that the U.S. Food and Drug Administration approved the orphan drug vandetanib for the treatment of medullary thyroid cancer that cannot be removed by surgery or that has spread to other parts of the body.

7 Apr 2011

Lupin grants Salix exclusive worldwide rights to rifaximin

Salix Pharmaceuticals, Ltd. today announced that as of March 31, 2011 Lupin Ltd. granted Salix exclusive worldwide rights (except for India) to exploit Lupin technology and technology jointly developed by Lupin and Salix for all rifaximin products for human use. This agreement expands the collaboration that Salix and Lupin entered into as of September 30, 2009.

6 Apr 2011

Cargill's new ideas on health and wellness, and cost management to be showcased at AMI Expo

Cargill will showcase new ideas in the areas of health and wellness, and cost management, specifically with regards to creating meat products with reduced sodium, healthier fats, and alternative lean beef raw materials options at The American Meat Institute Expo, April 13-16, 2011, in Chicago's McCormick Place.

6 Apr 2011

Researchers identify new gene that can influence person's risk of developing epilepsy

Vanderbilt University researchers have identified a new gene that can influence a person's risk for developing epilepsy. The findings, reported in the March 29 Proceedings of the National Academy of Sciences, could improve molecular diagnostic tools and point to novel therapeutic targets for epilepsy.

5 Apr 2011

Men who consume digoxin have 24% reduced risk of prostate cancer

Johns Hopkins scientists and their colleagues paired laboratory and epidemiologic data to find that men using the cardiac drug, digoxin, had a 24 percent lower risk for prostate cancer. The scientists say further research about the discovery may lead to use of the drug, or new ones that work the same way, to treat the cancer.

4 Apr 2011

Ther-Rx Corporation announces important initiative to reduce cost of Makena

As part of its ongoing efforts to ensure that high-risk women have access to FDA-approved Makena instead of unapproved, unregulated compounded drugs, Ther-Rx Corporation, a subsidiary of K-V Pharmaceutical Company, announced today important initiatives to reduce the cost of Makena (hydroxyprogesterone caproate injection) and encourage stakeholders to provide timely access to this important FDA-approved medication.

1 Apr 2011

New pill may protect DNA from radiation damage

The Japanese nuclear crisis has caused a surge in the demand of potassium iodide, causing shortages not only in Japan, but as far away as California, western Canada, and even southeastern Russia. Although potassium iodide does not provide generalized radiation protection because it only shields the thyroid, manufacturers and pharmacies are being bombarded with orders as the radiation hysteria mounts.

28 Mar 2011

German company steps up production of Radiogardase following Japan nuclear crisis

Heyltex Corporation is the exclusive U.S. distributor of Radiogardase® (Prussian Blue insoluble capsules), the only FDA-approved drug to treat people who have been internally contaminated with radioactive cesium (Cs-137), which is manufactured by Heyl chem. pharm. Fabrik Berlin GmbH in Germany.

25 Mar 2011

Study finds increased risk of VTE during first year of combination oral contraceptive usage

Bayer HealthCare Pharmaceuticals Inc. today announced that interim results from a large, prospective, observational cohort safety study offer insights into the increased risk of venous thromboembolism (VTE), or blood clots, which is a well-established risk in women who use combination oral contraceptives (COCs), also known as "the Pill".

25 Mar 2011

Biologists decipher molecular code regulating availability of brain channel linked to neuronal excitability

A key question in protein biochemistry is how proteins recognize "correct" interaction partners in a sea of cellular factors. Nowhere is that more critical to know than in the brain, where interactions governing channel protein activity can alter an organism's behavior.

23 Mar 2011

Obese teens have inflammation, insulin resistance, and high homocysteine levels despite feeling healthy

Obese teens may feel healthy, but blood tests show they have inflammation, insulin resistance, and high homocysteine levels, researchers report at the American Heart Association's Nutrition, Physical Activity and Metabolism/Cardiovascular Disease Epidemiology and Prevention 2011 Scientific Sessions.